Tekla Historical Income Statement
| HQL Stock | USD 13.79 0.04 0.29% |
Historical analysis of Tekla Life income statement accounts such as Total Revenue of 28.4 M or Gross Profit of 28.4 M can show how well Tekla Life Sciences performed in making a profits. Evaluating Tekla Life income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Tekla Life's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Tekla Life Sciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tekla Life Sciences is a good buy for the upcoming year.
Tekla |
About Tekla Income Statement Analysis
Tekla Life Sciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Tekla Life shareholders. The income statement also shows Tekla investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Tekla Life Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Tekla Life Sciences. It is also known as Tekla Life overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Tekla Life Sciences income statement and represents the costs associated with goods and services Tekla Life provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Tekla Life's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Tekla Life Sciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. At this time, Tekla Life's Income Tax Expense is quite stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 1.4M | 1.2M | 1.3M | 861.3K | Cost Of Revenue | 5.5M | 5.2M | 6.0M | 3.9M |
Tekla Life income statement Correlations
Click cells to compare fundamentals
Tekla Life Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tekla Life income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 2.1M | 4.1M | 3.0M | 167.9K | 193.1K | 183.4K | |
| Total Revenue | 124.1M | 65.7M | (103.3M) | 23.5M | 27.1M | 28.4M | |
| Gross Profit | 124.1M | 65.7M | (103.3M) | 23.5M | 27.1M | 28.4M | |
| Other Operating Expenses | 1.0M | 1.2M | 1.4M | 1.2M | 1.1M | 1.0M | |
| Operating Income | 123.1M | 64.5M | (104.6M) | 22.4M | 25.7M | 27.0M | |
| Ebit | 123.1M | 64.5M | (104.6M) | 22.4M | 25.7M | 27.0M | |
| Ebitda | 123.1M | 64.5M | (104.6M) | 22.4M | 25.7M | 37.3M | |
| Cost Of Revenue | 4.8M | 5.6M | 5.5M | 5.2M | 6.0M | 3.9M | |
| Total Operating Expenses | 1.0M | 1.2M | 1.4M | 1.2M | 1.3M | 861.3K | |
| Income Before Tax | 123.1M | 64.5M | (104.6M) | 22.4M | 25.7M | 20.3M | |
| Total Other Income Expense Net | (11.2K) | (7.8K) | 2.4K | (1.7K) | (2.0K) | (1.9K) | |
| Net Income | 123.1M | 64.5M | (104.6M) | 22.4M | 25.7M | 20.3M | |
| Selling General Administrative | 751.3K | 844.0K | 1.1M | 903.1K | 1.0M | 692.0K | |
| Net Income From Continuing Ops | 123.1M | 64.5M | (104.6M) | 22.4M | 20.1M | 16.0M | |
| Net Income Applicable To Common Shares | (70.5M) | 123.1M | 64.5M | (104.6M) | (94.1M) | (89.4M) | |
| Income Tax Expense | (2.1M) | (4.1M) | (3.0M) | 22.4M | 25.7M | 27.0M | |
| Interest Income | 164.8K | 68.7M | 50.1K | 204.4K | 184.0K | 174.8K | |
| Net Interest Income | 216.7K | 164.8K | 50.1K | 204.4K | 235.1K | 149.8K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.425 | Dividend Share 1.3 | Earnings Share 1.34 | Revenue Per Share 0.134 | Quarterly Revenue Growth 0.07 |
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.